Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision indicator was updated from v3.5.2 to v3.5.3, reflecting an incremental site/version change without altering the displayed clinical trial study content.SummaryDifference0.1%

- Check17 days agoChange DetectedAdded an erratum note for the JCO 2018 publication. Updated the publication revision from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check46 days agoChange DetectedRevision: v3.5.0 was added. Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page's revision label updated from v3.4.2 to v3.4.3. No trial content or visible details appear to be altered.SummaryDifference0.1%

- Check61 days agoChange DetectedUpdates shown are revision dates for the study record (e.g., 2026-03-04, 2027-02) and related metadata. No substantive changes to study design, eligibility criteria, outcomes, or locations are indicated.SummaryDifference0.3%

- Check82 days agoChange DetectedAdded site revision note 'Revision: v3.4.2'. Removed the operating-status notice about lapse in government funding and the earlier 'Revision: v3.4.1' note.SummaryDifference0.4%

Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.